Buried in the 2016 NBA summer spending spree, Festus Ezeli signed a team friendly deal. With today’s injection, we might know why.
The Ezeli signing, 2 years, around $15 million, is generally viewed as Olshey’s most savvy move of the offseason. A rim protector is at the top of nearly every NBA team’s list of needs. Amidst a cash influx like we’ve never seen, Ezeli wanted to sign with the Trail Blazers for a very cheap deal – including a team option for year two. It seemed too good to be true.
The news of today’s injection of bone marrow aspirate concentrate and Orthovisc sheds light into why Ezeli wanted to play for the Trail Blazers so badly: He might not have had many suitors.